Tanvex BioPharma Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Stephen Lam

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	3.3yrs

Actualizaciones recientes de la dirección

Recent updates

Does Tanvex BioPharma (TWSE:6541) Have A Healthy Balance Sheet?

Aug 07

Is Tanvex BioPharma (TPE:6541) Using Too Much Debt?

Mar 18

Are Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?

Jan 19

Does Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?

Nov 24

CEO

Stephen Lam

less than a year

Permanencia

Mr. Stephen Lam is Chief Executive Officer of Tanvex BioPharma, Inc. from September 5, 2024.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Stephen Lam	Chief Executive Officer	less than a year	sin datos	sin datos
Allen Chao	Founder & Honorary Chairman	no data	NT$111.00k	0.87% NT$ 99.8m
Angela Luan	CFO & Corporate Governance Officer	no data	sin datos	sin datos
Val Chen	VP of Finance Director of Ops. Mgmt.	no data	sin datos	sin datos
James Williamson	Accounting Officer	less than a year	sin datos	sin datos
Zheng Xia	Chief Technology Officer	9.9yrs	sin datos	sin datos
Linda Grillo	Director of Sales & Marketing	no data	sin datos	sin datos
Hsun-Chiang Hsieh	Secretary	no data	sin datos	sin datos

0.5yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de 6541 no se considera experimentado ( 0.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Allen Chao	Founder & Honorary Chairman	11.4yrs	NT$111.00k	0.87% NT$ 99.8m
David Hsia	Director	9.5yrs	sin datos	0.50% NT$ 56.9m
Lin-Cheng Chen	Chairman	less than a year	NT$5.00k	sin datos
Chi-Chuan Chen	Director	11.1yrs	NT$25.00k	0.010% NT$ 1.1m
Tamon Tseng	Director	11.1yrs	NT$25.00k	sin datos
Jin-Pau Tsai	Independent Director	9.5yrs	NT$682.00k	sin datos
Tay-Chang Wang	Independent Director	3.3yrs	NT$687.00k	sin datos
Jang-Yang Chang	Independent Director	2.4yrs	NT$570.00k	sin datos
Shang-Hsien Hsieh	Independent Director	less than a year	sin datos	sin datos
Chi-feng Chang	Independent Director	less than a year	sin datos	sin datos
Chun-Yen Chang	Independent Director	2.4yrs	NT$622.00k	sin datos

3.3yrs

Permanencia media

72yo

Promedio de edad

Junta con experiencia: La junta directiva de 6541 se considera experimentada (3.3 años de antigüedad promedio).

Tanvex BioPharma Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Tanvex BioPharma, Inc. Appoints Angela Luan as Chief Financial Officer, Effective November 11, 2024

High number of new directors

Tanvex BioPharma, Inc. Announces Change of CEO

High number of new directors

Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024

Tanvex BioPharma, Inc., Annual General Meeting, Jun 19, 2024

Recent updates

Third quarter 2024 earnings released: NT$1.94 loss per share (vs NT$3.78 loss in 3Q 2023)

Tanvex BioPharma, Inc. Appoints Angela Luan as Chief Financial Officer, Effective November 11, 2024

Tanvex BioPharma, Inc. to Report Q3, 2024 Results on Nov 08, 2024

High number of new directors

Tanvex BioPharma, Inc. Announces Change of CEO

Second quarter 2024 earnings released: NT$2.31 loss per share (vs NT$3.89 loss in 2Q 2023)

Tanvex BioPharma, Inc. (TWSE:6541) agreed to acquire Bora Biologics Co., Ltd. from Bora Pharmaceuticals Co., LTD. (TWSE:6472) and others for TWD 4.52 billion.

Does Tanvex BioPharma (TWSE:6541) Have A Healthy Balance Sheet?

Tanvex BioPharma, Inc. to Report Q2, 2024 Results on Aug 09, 2024

High number of new directors

Tanvex BioPharma, Inc. Appoints Val Chen as Corporate Governance Officer, Effective July 1, 2024

First quarter 2024 earnings released: NT$3.12 loss per share (vs NT$5.17 loss in 1Q 2023)

Tanvex BioPharma, Inc. to Report Q1, 2024 Results on May 07, 2024

Tanvex BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of TWD 1.44 billion.

Tanvex BioPharma, Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: NT$16.58 loss per share (vs NT$13.96 loss in FY 2022)

New major risk - Financial position

Tanvex BioPharma, Inc. Announces the Appointment of James Williamson as Accounting Officer

Tanvex BioPharma, Inc. Announces the Resignation of Ken Huang as Accounting Officer

Tanvex BioPharma, Inc. Announces Change of Chairman

Tanvex BioPharma, Inc. Announces Change of Corporate Governance Officer

Tanvex BioPharma, Inc. Announces the Resignation of Stacey Tsai as Acting Spokesperson and Corporate Governance Officer

Tanvex BioPharma, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

Second quarter 2023 earnings released: NT$3.89 loss per share (vs NT$3.63 loss in 2Q 2022)

New minor risk - Shareholder dilution

Tanvex BioPharma, Inc. announced that it expects to receive TWD 220 million in funding

Less than half of directors are independent

Tanvex BioPharma, Inc. announced a financing transaction

Tanvex BioPharma, Inc. Appoints Jang-Yang Chang as Independent Director

Less than half of directors are independent

Tanvex BioPharma, Inc., Annual General Meeting, Jun 17, 2022

Tanvex BioPharma, Inc. Announces the Appointment of K. H. Lin as CFO and Accounting Officer, Effective from February 18, 2022

Price target decreased to NT$53.00

Price target increased to NT$67.00

Is Tanvex BioPharma (TPE:6541) Using Too Much Debt?

Tanvex BioPharma, Inc. Enters into A License Agreement with Amgen

New 90-day high: NT$44.95

Are Institutions Heavily Invested In Tanvex BioPharma, Inc.'s (TPE:6541) Shares?

New 90-day low: NT$36.55

New 90-day low: NT$37.15

Does Tanvex BioPharma (TPE:6541) Have A Healthy Balance Sheet?

New 90-day high: NT$45.95

Earnings miss expectations

New 90-day low - NT$37.00

CEO

Permanencia

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad